Personalized SPM Profiling During Blood Coagulation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing methods fail to exploit the interactions between specialized pro-resolving mediators (SPMs) generated during blood coagulation and immune responses for making medical or therapeutic decisions.

Innovation Solution

A method involving metabololipidomic profiling of pro-thrombotic and pro-inflammatory mediators and SPMs during the time-course of clotting, using freeze-thaw permeabilization and purification, to obtain a personalized metabololipidomic profile for medical decision-making.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Loss of information

If blood samples are analyzed using conventional methods, then basic coagulation parameters can be measured, but interactions between SPMs generated during blood coagulation and immune responses cannot be exploited for making medical decisions

Engineering Contradiction:
Improveinformation on SPM-immune response interactionsVSAvoidcomplexity of metabololipidomic profiling system
Core Design Contradiction:
Loss of informationVSDevice complexity

Solution Approach 1:

The patent combines multiple analytical capabilities into a single metabololipidomic profiling system that simultaneously measures pro-thrombotic mediators, pro-inflammatory mediators, and specialized pro-resolving mediators (SPMs) in blood samples during coagulation, thereby capturing comprehensive information on SPM-immune response interactions without requiring separate complex systems

Inventive Principle:
Principle #5Merging (Combining)

Solution Approach 2:

The profiling system is designed to perform multiple functions: measuring coagulation parameters, detecting inflammatory mediators, and quantifying SPMs all within a single analytical platform, enabling the system to exploit previously undiscovered interactions between SPMs and immune responses across different physiological processes

Inventive Principle:
Principle #6Universality (Multi-functionality)

2Quantity of substance

If freeze-thaw permeabilization is used to release mediators, then pro-thrombotic and pro-inflammatory mediators and SPMs are effectively released, but additional processing steps are required

Engineering Contradiction:
Improverelease of mediatorsVSAvoidnumber of processing steps
Core Design Contradiction:
Quantity of substanceVSDevice complexity

Solution Approach 1:

The freeze-thaw permeabilization step is performed as a preliminary action before purification and analysis, effectively releasing pro-thrombotic and pro-inflammatory mediators and SPMs from blood cells in advance, which simplifies subsequent processing by making the mediators readily available for extraction and measurement

Inventive Principle:
Principle #10Preliminary action

3Loss of information

If adenosine is removed ex vivo, then a second SPM cluster is unmasked and enhanced in the profile, but an additional treatment step is required

Engineering Contradiction:
Improvedetection of second SPM clusterVSAvoidnumber of treatment steps
Core Design Contradiction:
Loss of informationVSDevice complexity

Solution Approach 1:

Adenosine is selectively removed (taken out) from the blood sample through ex vivo treatment before analysis, which unmasks a previously hidden second SPM cluster in the metabololipidomic profile, allowing detection of additional mediators that were previously obscured by adenosine interference

Inventive Principle:
Principle #2Taking out (Extraction)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Enables accurate medical decisions by identifying specific SPM clusters indicative of a patient's health status, aiding in disease diagnosis and therapeutic assessment.

Implementation Method 1

the sample is permeabilized by freeze-thaw to release the pro-thrombotic and pro-inflammatory mediators (eicosanoids) and the SPMs

Methodology Applied
Scientific EffectFreeze-thaw permeabilization: Freezing

Data Source

PatentEP3544684B1Personalized metabolomic profiling of specialized pro-resolving mediators
Publication Date: 2025.09.17 THE BRIGHAM & WOMEN S HOSPITAL INC
  • EP3544684B1 patent drawingFigure 1A~1B
  • EP3544684B1 patent drawingFigure 1C
  • EP3544684B1 patent drawingFigure 1D

AI summary

Disclosed herein is a method of providing a metabololipidomic profile and SPM signature on the progress of the innate host defense response following blood clotting. The method can include the step of taking one or more measurements in a patient's blood sample, wherein the sample is obtained during the time-course of clotting or coagulation or following clotting or coagulation, of pro-thrombotic and pro-inflammatory mediators (eicosanoids) and specialized pro-resolving mediators SPMs. From these measurements, a personalized metabololipidomic profile can be obtained. By comparing the measurement to that taken from normal or reference blood, a comparison profile can be developed. The profile comparison profile can then be used to make a medical or therapeutic decision.